Your browser doesn't support javascript.
loading
Low-dose IL-2 enhances the generation of IL-10-producing immunoregulatory B cells.
Inaba, Akimichi; Tuong, Zewen Kelvin; Zhao, Tian X; Stewart, Andrew P; Mathews, Rebeccah; Truman, Lucy; Sriranjan, Rouchelle; Kennet, Jane; Saeb-Parsy, Kourosh; Wicker, Linda; Waldron-Lynch, Frank; Cheriyan, Joseph; Todd, John A; Mallat, Ziad; Clatworthy, Menna R.
Afiliação
  • Inaba A; Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge, UK.
  • Tuong ZK; Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge, UK.
  • Zhao TX; Cellular Genetics, Wellcome Sanger Institute, Hinxton, UK.
  • Stewart AP; Department of Medicine, Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK.
  • Mathews R; Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge, UK.
  • Truman L; Molecular Immunity Unit, University of Cambridge Department of Medicine, Cambridge, UK.
  • Sriranjan R; Ear, Nose Throat Department, West Suffolk Hospital, Bury St Edmunds, UK.
  • Kennet J; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Saeb-Parsy K; Wellcome-MRC Institute of Metabolic Science-Metabolic Research Laboratories and Medical Research Council Metabolic Diseases Unit, University of Cambridge, Cambridge, UK.
  • Wicker L; Department of Surgery, University of Cambridge, Cambridge, UK.
  • Waldron-Lynch F; National Institute for Health Research Cambridge Biomedical Research Centre, Cambridge, UK.
  • Cheriyan J; Medical Sciences Division, University of Oxford, Oxford, UK.
  • Todd JA; Novartis Institutes for BioMedical Research, Autoimmunity Transplantation Inflammation, Basel, Switzerland.
  • Mallat Z; Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Cambridge, UK.
  • Clatworthy MR; Wellcome Centre for Human Genetics, Nuffield Department of Medicine, University of Oxford, Oxford, UK.
Nat Commun ; 14(1): 2071, 2023 04 12.
Article em En | MEDLINE | ID: mdl-37045832
Dysfunction of interleukin-10 producing regulatory B cells has been associated with the pathogenesis of autoimmune diseases, but whether regulatory B cells can be therapeutically induced in humans is currently unknown. Here we demonstrate that a subset of activated B cells expresses CD25, and the addition of low-dose recombinant IL-2 to in vitro stimulated peripheral blood and splenic human B cells augments IL-10 secretion. Administration of low dose IL-2, aldesleukin, to patients increases IL-10-producing B cells. Single-cell RNA sequencing of circulating immune cells isolated from low dose IL2-treated patients reveals an increase in plasmablast and plasma cell populations that are enriched for a regulatory B cell gene signature. The transcriptional repressor BACH2 is significantly down-regulated in plasma cells from IL-2-treated patients, BACH2 binds to the IL-10 gene promoter, and Bach2 depletion or genetic deficiency increases B cell IL-10, implicating BACH2 suppression as an important mechanism by which IL-2 may promote an immunoregulatory phenotype in B cells.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Interleucina-10 Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Interleucina-2 / Interleucina-10 Idioma: En Ano de publicação: 2023 Tipo de documento: Article